Details of the Drug

General Information of Drug (ID: DMUDJZM)

Drug Name

Dextromethorphan

Synonyms

Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Common cold	CA00	Approved	[1]
Cough	MD12	Approved	[2]
Fever	MG26	Approved	[1]
Headache	8A80-8A84	Approved	[1]
Rhinitis	FA20	Approved	[1]
Vasomotor/allergic rhinitis	CA08	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

271.4

Logarithm of the Partition Coefficient (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 17.8 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.9 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.86 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Elimination: 0.19% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 30 hours [5]
Metabolism: The drug is metabolized via the N-demethylated to 3-methoxymorphinan by CYP3A4, CYP2D6, and CYP2C9 or O-demethylated to dextrorphan by CYP2D6 and CYP2C9 [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.878 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 5-6.7 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 15 mg/mL [4]

Chemical Identifiers

Formula: C18H25NO
IUPAC Name: (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
Canonical SMILES: CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
InChI: InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
InChIKey: MKXZASYAUGDDCJ-NJAFHUGGSA-N

Cross-matching ID

PubChem CID: 5360696
ChEBI ID: CHEBI:4470
CAS Number: 125-71-3
DrugBank ID: DB00514
TTD ID: D09OBB
VARIDT ID: DR00891
INTEDE ID: DR0476
ACDINA ID: D00177

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[13]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[14]
Cholesterol 24-hydroxylase (CYP46A1)	DEKP5HX	CP46A_HUMAN	Substrate	[15]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[16]
Cytochrome P450 130A1 (cyp130)	DE6CQ0I	CP130_MYCTU	Substrate	[17]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Regulation of Drug Effects	[18]
Beta-hexosaminidase subunit beta (HEXB)	OTROYLCR	HEXB_HUMAN	Protein Interaction/Cellular Processes	[19]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Protein Interaction/Cellular Processes	[19]
Cholesterol 24-hydroxylase (CYP46A1)	OTJ27FOX	CP46A_HUMAN	Biotransformations	[15]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Regulation of Drug Effects	[18]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[20]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[21]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Biotransformations	[21]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Protein Interaction/Cellular Processes	[19]
Mas-related G-protein coupled receptor member X2 (MRGPRX2)	OT2XA799	MRGX2_HUMAN	Protein Interaction/Cellular Processes	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor sigma 1 (OPRS1)	DTT	SIGMAR1	2.77E-06	-0.12	-0.62
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.88E-01	-1.69E-05	-1.28E-04
Cholesterol 24-hydroxylase (CYP46A1)	DME	CYP46A1	1.79E-06	-3.32E-01	-6.53E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dextromethorphan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Dextromethorphan and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[22]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Oliceridine.	Acute pain [MG31]	[23]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Dextromethorphan caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[24]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Dextromethorphan and Linezolid.	Bacterial infection [1A00-1C4Z]	[25]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Dihydrocodeine.	Chronic pain [MG30]	[23]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Dextromethorphan and Levomilnacipran.	Chronic pain [MG30]	[25]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Ethanol.	Cystitis [GC00]	[26]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Dextromethorphan and Sertraline.	Depression [6A70-6A7Z]	[25]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Dextromethorphan and Vilazodone.	Depression [6A70-6A7Z]	[25]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Dextromethorphan and Nefazodone.	Depression [6A70-6A7Z]	[25]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Dextromethorphan caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[27]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Dextromethorphan and Selegiline.	Depression [6A70-6A7Z]	[22]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Dextromethorphan and Vortioxetine.	Depression [6A70-6A7Z]	[25]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Dextromethorphan and Isocarboxazid.	Depression [6A70-6A7Z]	[22]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Dextromethorphan and Milnacipran.	Depression [6A70-6A7Z]	[25]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Dextromethorphan and Tranylcypromine.	Depression [6A70-6A7Z]	[22]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Dextromethorphan and Desvenlafaxine.	Depression [6A70-6A7Z]	[25]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Dextromethorphan and Phenelzine.	Depression [6A70-6A7Z]	[22]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Dextromethorphan and Trazodone.	Depression [6A70-6A7Z]	[25]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Esketamine.	Depression [6A70-6A7Z]	[24]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Dextromethorphan and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[25]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Dextromethorphan caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Dextromethorphan caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[24]
Terbinafine	DMI6HUW	Major	Decreased metabolism of Dextromethorphan caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[27]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Dextromethorphan and Procarbazine.	Hodgkin lymphoma [2B30]	[22]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Dextromethorphan caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Dextromethorphan caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Dextromethorphan caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[24]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Dextromethorphan caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[24]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Dextromethorphan caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[28]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Dextromethorphan caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[24]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Dextromethorphan caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Dextromethorphan caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[24]
Halofantrine	DMOMK1V	Moderate	Decreased metabolism of Dextromethorphan caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[24]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Dextromethorphan caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[29]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Flibanserin.	Mood disorder [6A60-6E23]	[30]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Dextromethorphan caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[24]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Thalidomide.	Multiple myeloma [2A83]	[31]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Dextromethorphan and Ozanimod.	Multiple sclerosis [8A40]	[22]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dextromethorphan caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Dextromethorphan caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Dextromethorphan caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Dextromethorphan caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[32]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Dextromethorphan and Granisetron.	Nausea/vomiting [MD90]	[33]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Dextromethorphan and Dolasetron.	Nausea/vomiting [MD90]	[33]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Dextromethorphan and Ondansetron.	Nausea/vomiting [MD90]	[33]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Dextromethorphan caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[34]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Dextromethorphan and Sibutramine.	Obesity [5B80-5B81]	[35]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Dextromethorphan and Lorcaserin.	Obesity [5B80-5B81]	[36]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Dextromethorphan and Dexfenfluramine.	Obesity [5B80-5B81]	[25]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Dextromethorphan and Levomethadyl Acetate.	Opioid use disorder [6C43]	[30]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Apraclonidine.	Optic nerve disorder [9C40]	[37]
Valdecoxib	DMAY7H4	Minor	Decreased metabolism of Dextromethorphan caused by Valdecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[38]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Dextromethorphan caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[24]
Butorphanol	DM5KYPJ	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Butorphanol.	Pain [MG30-MG3Z]	[23]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Oxymorphone.	Pain [MG30-MG3Z]	[23]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Levorphanol.	Pain [MG30-MG3Z]	[23]
Dezocine	DMJDB0Y	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Dezocine.	Pain [MG30-MG3Z]	[23]
Nalbuphine	DMOSQGU	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Nalbuphine.	Pain [MG30-MG3Z]	[23]
Buprenorphine	DMPRI8G	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Buprenorphine.	Pain [MG30-MG3Z]	[23]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of Dextromethorphan and Hydrocodone.	Pain [MG30-MG3Z]	[23]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Dextromethorphan and Safinamide.	Parkinsonism [8A00]	[22]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Dextromethorphan and Rasagiline.	Parkinsonism [8A00]	[22]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dextromethorphan caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[39]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Dextromethorphan caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[40]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Dextromethorphan caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[24]
Levomepromazine	DMIKFEL	Major	Decreased metabolism of Dextromethorphan caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[27]
Fluphenazine	DMIT8LX	Moderate	Decreased metabolism of Dextromethorphan caused by Fluphenazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[24]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Dextromethorphan caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[24]
Thioridazine	DM35M8J	Moderate	Decreased metabolism of Dextromethorphan caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[24]
Perphenazine	DMA4MRX	Moderate	Decreased metabolism of Dextromethorphan caused by Perphenazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[24]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dextromethorphan caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[41]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Dextromethorphan and Tizanidine.	Tonus and reflex abnormality [MB47]	[42]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Dextromethorphan caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[24]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Dextromethorphan caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[24]
-----------


⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propyl gallate	E00075	4947	Antimicrobial preservative; Antioxidant
Quinoline yellow WS	E00309	24671	Colorant
Saccharin sodium anhydrous	E00443	656582	Flavoring agent
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate	E00445	2723816	Antimicrobial preservative
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dextromethorphan 30 mg tablet	30 mg	Disintegrating Oral Tablet	Oral
Dextromethorphan 15 mg capsule	15 mg	Oral Capsule	Oral
Dextromethorphan 15mg/5ml Syrup	15mg/5ml	Syrup	Oral
Dextromethorphan 10mg capsule	10mg	Capsule	Oral
Dextromethorphan 20mg capsule	20mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Dextromethorphan FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6953).
3	Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM: Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004 Oct;44(10):1132-42. doi: 10.1177/0091270004269521.
4	BDDCS applied to over 900 drugs
5	Dextromethorphan Toxicity .
6	Rodriguez-Gascon A, Canut-Blasco A: Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter. 2019 May;32 Suppl 1:19-24.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
9	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
10	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
11	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
14	Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82.
15	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
16	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
17	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
18	Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul;44(7):708-14. doi: 10.1177/0091270004266624.
19	Dextromethorphan - A widely-used cough suppressant - Induces local anaphylaxis via MRGPRX2 on mast cells. Chem Biol Interact. 2020 Oct 1;330:109248. doi: 10.1016/j.cbi.2020.109248. Epub 2020 Aug 29.
20	Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother. 2011 Jan;45(1):e1. doi: 10.1345/aph.1P301. Epub 2010 Dec 14.
21	Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
22	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
23	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
24	Cerner Multum, Inc. "Australian Product Information.".
25	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA "The influence of CYP2d6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans." Clin Pharmacol Ther 60 (1996): 295-307. [PMID: 8841152]
28	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
29	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
30	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
31	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
32	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
33	Canadian Pharmacists Association.
34	Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42. [PMID: 8513655]
35	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
36	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
37	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
38	Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
39	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
40	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
41	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
42	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.